Life Science AllianceBiochemistryPeer-reviewed journal article
Oligomerization of PRMT1 Regulated RNA-Binding Protein Cascade Promotes Pancreatic Ductal Adenocarcinoma
Yanxia Ru, Xinyi Zhou, Xijiao Wang, Wenxin SuniD, Yaohui HeiD, Guo-Sheng HuiD, Wenjuan Li, Die HuiD, Meizhi Jiang, Zhiming SuiD, Fengfeng NiuiD, Gang CheniD, Jin-Zhang ZengiD, Sen‐Fang SuiiD, Wen LiuiD, Yaowang LiiD, Siming CheniD
Abstract
PRMT1 is the predominant type I protein arginine methyltransferase responsible for generating monomethylarginine and asymmetric dimethylarginine (MMA and ADMA) in various protein substrates. It regulates numerous biological processes, including RNA metabolism, mRNA splicing, DNA damage repair, and chromatin dynamics. The crystal structure of rat PRMT1 has been previously reported as a homodimer; however, higher-order oligomeric species of human PRMT1 have been observed in vivo, and their structural basis remains elusive. In this study, we present the cryo-EM structure of human PRMT1 in its oligomeric form, revealing novel interfaces crucial for PRMT1 self-assembly and normal function. PRMT1 shows a strong preference for intrinsically disordered RGG/RG motifs, which are commonly found in RNA-binding proteins (RBPs), highlighting its critical role in regulating RNA metabolism. In vitro studies indicate that disrupting PRMT1 oligomerization impairs its binding affinity for RGG motif substrates, thereby reducing arginine methylation levels on these substrates. This finding emphasizes the essential role of the oligomeric state of PRMT1 in its function with RGG motif-containing RBPs. In vivo, the loss of PRMT1 oligomerization leads to decreased global ADMA levels in pancreatic ductal adenocarcinoma (PDAC) cells and inhibits PDAC tumor growth. Collectively, we propose that PRMT1 oligomerization, rather than mere dimerization, is sufficient for PRMT1-driven PDAC tumor growth, offering novel insights into the potential therapeutic targeting of PRMT1 oligomeric forms in PDAC. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=177 SRC="FIGDIR/small/627716v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@1ed6232org.highwire.dtl.DTLVardef@1c9e688org.highwire.dtl.DTLVardef@3e2c43org.highwire.dtl.DTLVardef@1cbf33e_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: protein structure
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 5
- FWCI
- 1.38
- Field percentile
- top 20%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transcriptomic and proteomic regulation through abundant, dynamic, and independent arginine methylation by Type I and Type II PRMTs
Maxim I. Maron, Stephanie M. Lehman, … David Shechter·iSciencePeer-reviewed·Aug 11, 2021
- A systematic survey of PRMT interactomes reveals the key roles of arginine methylation in the global control of RNA splicing and translation
Huanhuan Y. Wei, Xiaojuan Fan, … Zefeng Wang·中国科学通报:英文版Peer-reviewed·Jan 14, 2021
- Structures of pUG-fold RNA bound to DNMT1 reveal a mechanism for RNA-mediated epigenetic regulation
Jessica J. Song, Thomas R. Cech, Vignesh Kasinath·bioRxiv·Sep 3, 2026
- Protein arginine-methyltransferase 1 (PRMT1): a new pharmacological target in cholangiocarcinoma
Emiliana Valbuena-Goiricelaya, Jasmin Elurbide, … Matias Antonio Avila·bioRxiv·May 29, 2026
- Molecular basis for substrate recruitment to the PRMT5 methylosome
K. M. Mulvaney, C. Blomquist, … W. R. Sellers·bioRxiv·Aug 22, 2020
- PRMT activity promotes global 3' UTR shortening in proliferating cells
Llywelyn Griffith, Charlotte Capitanchik, … Jernej Ule·bioRxiv·Mar 6, 2025